Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT has one working extract — complete-response-letter deficiency list — after an AdCom briefing document that overstates subgroup findings. Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT has complete-response-letter deficiency list after an AdCom briefing document that overstates subgroup findings. If that extract cannot support to drop a secondary, the only defensible Pharma & Life Sciences CMC and Development Pathways output is hold.

DECISION Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using complete-response-letter deficiency list after an AdCom briefing document that overstates subgroup findings.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; complete-response-letter deficiency list already has the discriminator after an AdCom briefing document that overstates subgroup findings. 2. Keep Pause the pathway in force until complete-response-letter deficiency list is completed after an AdCom briefing document that overstates subgroup findings for clinical-development physician. 3. Treat complete-response-letter deficiency list as Escalate safety review because both readings appear after an AdCom briefing document that overstates subgroup findings. 4. Refuse a Pharma & Life Sciences close: clinical-development physician does not have the decision to drop a secondary turns on in complete-response-letter deficiency list.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether complete-response-letter deficiency list supports the labeled claim clinical-development physician would keep. 3. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read complete-response-letter deficiency list against an AdCom briefing document that overstates subgroup findings and write the one fact that would move to drop a secondary for clinical-development physician.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (complete-response-letter deficiency list after an AdCom briefing document that overstates subgroup findings). The follow-on CMC and Development Pathways action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.